1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
0 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
Predictive Oncology approves increase to equity incentive plan and issuance of pre‑funded warrants
At the annual meeting, shareholders voted to increase the 2024 Equity Incentive Plan by 1,000,000 shares and to issue 14,903,393 common shares that will be issued upon exercise of pre‑funded warrants. The elections of directors Daniel E. Handley and Chuck Nuzum were confirmed and KPMG was appointed as independent auditors. Predictive Oncology also reported a significant net loss in Q3 2025, but said it has regained compliance with NASDAQ’s minimum stockholders’ equity requirement and is pursuing initiatives to enter the AI infrastructure market. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 2.82M | 123,699.49% |
| Gross profit | 176.69K | 1,440.23% |
| Net profit | -15.08M | 758.24% |
| EBITDA | -3.52M | 129.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €103.67M |
Number of shares | 11.49M |
52-week high/low | €27.71 - €0.89 |
| Dividends | No |
Beta | 3.47 |
P/E ratio | -0.07 |
PEG ratio | 0.00 |
P/B ratio | 6.04 |
P/S ratio | 36.82 |
Company profile
| Name | Predictive Oncology |
| CEO | Christopher Miglino |
| Employees | 14 |
Discover assets
Shareholders of Predictive Oncology also invest in the following assets
